Navigation Links
Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
Date:12/16/2008

onstrated that the Intermezzo(R) 1.75 mg and 3.5 mg doses, when used at the time of a middle of the night awakening, significantly shortened the time for patients to return to sleep as compared to placebo, with no evidence of next day residual sedative effects with either dose. Further, when patients used the 3.5 mg dose, the study also indicated statistically significant improvements in total sleep time, sleep efficiency, subjective number of post-dose awakenings, sleep quality, level of refreshed sleep, and next day ability to function. Transcept believes that these are the lowest zolpidem doses that have been reported to be statistically superior to placebo in producing sleep.

The second Phase 3 clinical trial was a double-blind, placebo-controlled outpatient study in which 294 patients used either Intermezzo(R) 3.5 mg or placebo at home, at the time they awakened in the middle of the night and had difficulty returning to sleep. This Phase 3 clinical trial also met its primary endpoint of significantly reducing the time required for the patient to return to sleep versus placebo. After dosing and returning to sleep, patients in the outpatient study who were randomized to Intermezzo(R) also reported fewer subsequent awakenings and less time awake during the remainder of the night. There was no evidence of next day residual sedative effects after middle of the night use of Intermezzo(R) versus placebo.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the nigh
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... January 23, 2015 Biofertilizers stimulate microbial ... as nitrogen and phosphorous through the activities in the ... is increasing due to the stress on reducing environmental ... , The report defines and segments the bio fertilizers ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Shimadzu ... new UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength scanning ... instrument is ideal for applications in a variety ... science. , The user-friendly UV-1280 enables intuitive operation, ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart ... 2014 was a record-breaking year across the board for the ... Smart Data Platform and our Smart Data solutions, our customers ... data which led to record growth for the company in ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf ... portfolio of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 ... 5424/5424 R and receive the following:, , ... or Eppendorf Reference 2 ,     3 Free ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... WILMINGTON, Del., Feb. 29 AstraZeneca (NYSE:,AZN) today ... Application,(sNDA) to the U.S. Food and Drug Administration ... Tablets to seek,approval for the treatment of major ... therapy in adult patients., MDD affects 15 ...
... Feb. 29 Syngenta,announced today that the 2007 ... the US Securities and Exchange Commission., The ... http://www.syngenta.com ,in the Investor Relations section; hard ... shareholders free of charge upon request., Syngenta ...
... German . , Automation makes a business ... of small and medium-sized enterprises (SMEs). However, for many ... inflexible, too big or too expensive. SMErobot now promises ... technology in small and medium-sized businesses: this EU project ...
Cached Biology Technology:AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 8Filing of 2007 Annual Report on Form 20-F 2SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 2SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 3SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 4
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... 2015  Analyst Report Issued by Small Cap IR. In 2011, ... planet-wide, transactions at merchants on the leading payment cards rose ... credit, debit, and prepaid cards reached 6.54 billion.  Eight million ... card usage in 2012, and credit and debit card fraud ...
(Date:12/24/2014)... in December 2014, the 1U™ app has helped ... remember their usernames and passwords through replacing the antiquated system ... people who have struggled to remember usernames and passwords, ... on redefining identity, announced today that it is offering the ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... Providing clues into why the severity of a common ... new Johns Hopkins study shows that each one of three ... off a unique reaction in the nerve cells it invades. ... 25 percent of people worldwide, can trigger or exacerbate psychotic ...
... will play a key role in helping to conserve the ... conservation and research station located in the Manu Biosphere Reserve ... station for the San Diego Zoo and marks a significant ... is located in the western Amazon and is recognized by ...
... research may be relevant to the effects of ... development of obesity in her children. An ... suggests that a high-fat, high-carbohydrate diet causes oxidative ... the offspring to obesity and diabetes. Feeding rats ...
Cached Biology News:Toxoplasmosis: The strain explains severity of infection 2San Diego Zoo Global joins effort to conserve the Amazonian rain forest through Peru field station 2Antioxidants in pregnancy prevent obesity in animal offspring 2
Request Info...
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Biology Products: